FDA identifies 20 drugs that need approved risk eval, strategy

Share this article:
FDA identified 20 Rx drugs and biologics that must have an approved risk evaluation and mitigation strategy, including GlaxoSmith-Kline's Lotronex, Novartis' Clozaril, Cephalon's Actiq, Hoffmann-LaRoche's Accutane, Celgene's Revlimid and Thalomid, Danco's Mifeprex and Biogen Idec's Tysabri.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.